title: Antiparasitic therapy.
abstract: Parasitic diseases affect more than 2 billion people globally and cause substantial morbidity and mortality, particularly among the world's poorest people. This overview focuses on the treatment of the major protozoan and helminth infections in humans. Recent developments in antiparasitic therapy include the expansion of artemisinin-based therapies for malaria, new drugs for soil-transmitted helminths and intestinal protozoa, expansion of the indications for antiparasitic drug treatment in patients with Chagas disease, and the use of combination therapy for leishmaniasis and human African trypanosomiasis.
authors.affiliation: Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA 94305-5107, USA.
authors.forename: Shanthi
authors.initials: S
authors.lastname: Kappagoda
authors.forename: Upinder
authors.initials: U
authors.lastname: Singh
authors.forename: Brian G
authors.initials: BG
authors.lastname: Blackburn
mesh_terms: D000562:Amebiasis / Q000188:drug therapy; D000871:Anthelmintics / Q000627:therapeutic use*; D000977:Antiparasitic Agents / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D002590:Cestode Infections / Q000188:drug therapy; D014355:Chagas Disease / Q000188:drug therapy; D004351:Drug Resistance; D005873:Giardiasis / Q000188:drug therapy; D006373:Helminthiasis / Q000188:drug therapy*; D006801:Humans; D007896:Leishmaniasis / Q000188:drug therapy; D008288:Malaria / Q000188:drug therapy; D009349:Nematode Infections / Q000188:drug therapy; D010272:Parasitic Diseases / Q000188:drug therapy; D011528:Protozoan Infections / Q000188:drug therapy*; D014123:Toxoplasmosis / Q000188:drug therapy; D014201:Trematode Infections / Q000188:drug therapy; D014353:Trypanosomiasis, African / Q000188:drug therapy
chemical_list: D000871:Anthelmintics; D000977:Antiparasitic Agents; D000981:Antiprotozoal Agents